To read the full story, subscribe or sign in.

Prerevenue med-tech Venus raises $308M on HKEX

Dec. 10, 2019

BEIJING – Chinese transcatheter heart valve developer Venus Medtech (Hangzhou) Inc. on Tuesday saw its share prices jump around 20% on its debut on the Hong Kong Stock Exchange (HKEX), an excellent start for a prerevenue med-tech IPO.

Financings Medical technology Cardiovascular IPO Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for March 9, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

Cross section illustration of HIV virus parts

Anticancer drug exerts potent HIV antiviral effects

BioWorld Science

A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....